FXIII (Factor XIII) is a Ca 2 + -dependent enzyme which forms covalent ε-(γ -glutamyl)lysine cross-links between the γ -carboxy-amine group of a glutamine residue and the ε-amino group of a lysine residue. FXIII was originally identified as a protein involved in fibrin clot stabilization; however, additional extracellular and intracellular roles for FXIII have been identified which influence thrombus resolution and tissue repair. The present review discusses the substrates of FXIIIa (activated FXIII) involved in thrombosis and wound healing with a particular focus on: (i) the influence of plasma FXIIIa on the formation of stable fibrin clots able to withstand mechanical and enzymatic breakdown through fibrin-fibrin cross-linking and cross-linking of fibrinolysis inhibitors, in particular α 2 -antiplasmin; (ii) the role of intracellular FXIIIa in clot retraction through cross-linking of platelet cytoskeleton proteins, including actin, myosin, filamin and vinculin; (iii) the role of intracellular FXIIIa in cross-linking the cytoplasmic tails of monocyte AT 1 Rs (angiotensin type 1 receptors) and potential effects on the development of atherosclerosis; and (iv) the role of FXIIIa on matrix deposition and tissue repair, including cross-linking of extracellular matrix proteins, such as fibronectin, collagen and von Willebrand factor, and the effects on matrix deposition and cell-matrix interactions. The review highlights the central role of FXIIIa in the regulation of thrombus stability, thrombus regulation, cell-matrix interactions and wound healing, which is supported by observations in FXIII-deficient humans and animals.
INTRODUCTION
FXIII (Factor XIII) structure and mechanism of action FXIII is a transglutaminase which catalyses the formation of covalent ε-(γ -glutamyl)lysine cross-links between the γ -carboxyamine group of a glutamine (amine acceptor) and the ε-amino group of a lysine (amine donor) residue. Plasma FXIII has a heterotetrameric structure composed of pairs of A subunits (83 kDa) and B subunits (80 kDa) held together by non-covalent interactions (FXIII-A2B2) [1, 2] , whereas cFXIII-A (cellular FXIII) exists as an A subunit homodimer [1, 3] . The FXIII-A subunit contains the active site of the enzyme and is predominantly synthesised by cells of the monocyte/macrophage, megakaryocyte/platelet, chondrocyte and osteoblast/osteocyte lineages. [2, 4] . However hepatocytes have also been reported to express low levels of the enzyme [5, 6] . The FXIII-B subunit acts as a carrier protein in plasma for the hydrophobic A subunit and is Abbreviations: ACE, angiotensin-converting enzyme; AngII, angiotensin II; AT 1 R, angiotensin type 1 receptor; COAT, collagen-and thrombin-activated; FV, Factor V; FVa, activated FV; FXa, activated Factor X; FXIII, Factor XIII; FXIIIa, activated FXIII; cFXIII-A, cellular FXIII; GPIIb etc., glycoprotein IIb etc.; PA, plasminogen activator; PAI, PA inhibitor; TAFI, thrombin activatable fibrinolysis inhibitor; TAFIa, activated TAFI; TG2, tissue transglutaminase 2; t-PA, tissue-type PA; u-PA, urokinase-type PA; vWF, von Willebrand factor.
Correspondence: Dr Angela M. Carter (email a.carter@leeds.ac.uk) synthesized and secreted by hepatocytes [7] . The cellular origin of plasma FXIII-A is unclear. Inbal et al. [8] proposed that platelets were the source of plasma FXIII-A; however, in two independent transgenic mouse models of thrombocytopenia, plasma levels of FXIII-A were normal, suggesting that, instead of platelets, cells of the monocyte lineage may be the source of plasma FXIII-A [9] .
Activation of plasma FXIII-A2B2 is initiated upon the cleavage of the peptide bond between Arg 37 and Gly 38 of FXIII-A by thrombin and the release of the 37-amino-acid activation peptide [10] . Binding of FXIII-A2B2 via FXIII-B to non-cross-linked fibrin polymers allows the optimal orientation for FXIII-A cleavage of the activation peptide [11] . In the presence of Ca 2 + and fibrin [12] , thrombin-cleaved FXIII-A undergoes several conformational changes; initially FXIII-B dissociates from FXIII-A and then re-orientation of FXIII-A leads to exposure of the active site, forming FXIIIa (activated FXIII) [13] (Figure 1) . Once cross-linking of the fibrin γ -chains occurs, the effect of fibrin on FXIII-A activation is lost, suggesting that fibrin cross-linking down-regulates FXIII-A activation [14] . Activation of cFXIII-A occurs in the presence of Ca 2 + alone, with intracellular Ca 2 + concentrations above 2 mM required for activation [15] . The active site of FXIII-A contains a catalytic triad made up of Cys 314 , which is required for the catalytic activity, and His 373 and Asp 396 , which are hydrogen-bonded to Cys 314 [16, 17] . FXIIIa uses a double displacement mechanism for cross-linking proteins, which has been described in detail previously [18] . In the initial stage of cross-link formation, Cys 314 attacks the glutamine γ -carboxyamide group of a glutamine acceptor protein, displacing a molecule of ammonia to form a thioester intermediate. In the second stage, the reactive thioester intermediate is attacked by the lysine ε-amino group of the amine donor protein, displacing Cys 314 and resulting in the formation of an isopeptide bond between the two substrate proteins and the release of FXIIIa (Figure 2 ). In the absence of lysine residues, water reacts with the thioester intermediate converting glutamine into glutamic acid [18] .
A variety of methods have been employed to identify and characterize the substrates for FXIIIa. Potential glutamine sites in proteins have been identified by FXIIIa-catalysed incorporation of primary amines, such as putrescine [19] [20] [21] [22] [23] [24] [25] , dansylcadaverine [21, 22, [26] [27] [28] and 5-(biotinamido)pentylamine [29, 30] . Alternatively, labelled synthetic peptides have been designed to incorporate into the lysine residues of FXIIIa substrates [26] . In several cases, reactive glutamine and lysine residues have been characterized by MS and Edman sequencing analysis [19, [29] [30] [31] , as summarized in Figure 2 . Recombinant proteins containing mutations in the glutamine [29, 32] and lysine sites have also been used to confirm the importance of these residues in the cross-linking reaction.
The following sections provide an overview of the identification and characterization of key substrates for FXIIIa (summarized in Table 1 ), focusing on those substrates with known or potential roles in thrombosis and wound healing to provide insights into the potentially diverse roles of FXIIIa in the pathophysiology of cardiovascular disease.
SUBSTRATES OF FXIII INFLUENCING THE COMPONENTS OF THE COAGULATION CASCADE
The coagulation cascade is activated upon vascular damage, resulting in the sequential cleavage and activation of coagulation factors and culminating in thrombin generation and fibrin formation. FXIIIa-dependent cross-linking of fibrin results in the formation of a stable fibrin meshwork that is able to withstand mechanical pressures and enzymatic breakdown ( Figure 3 ) [33] .
Inter-molecular fibrin chain cross-linking
Fibrin is formed by thrombin-mediated cleavage of fibrinogen (2Aα, 2Bβ and 2γ ) in the final stages of activation of the coagulation cascade. Thrombin sequentially cleaves the short N-terminal fibrinopeptides A and B from the fibrinogen Aα and Bβ chains respectively, to initiate fibrin protofibril formation, lateral aggregation and formation of trimolecular and tetramolecular branch points, which ultimately lead to the formation of a complex fibrin network [34, 35] . The fibrin clot is stabilized by FXIIIa-induced cross-linking between fibrin γ chains and fibrin α chains [33, 36] , which increase the stiffness and reduce the stretch of the fibrin Methodology for the identification of FXIII-A substrates FXIIIa forms an isopeptide bond between a glutamine-containing protein and a lysine-containing protein. Alternatively, the lysine-and glutamine-containing proteins can be replaced by synthetic peptides in the cross-linking reaction. FXIII-A substrates have been identified by MS and sequence information obtained by Edman sequencing.
network [37] , thus providing the important structural framework of a thrombus. FXIIIa rapidly forms cross-links between γ chains of fibrin molecules to form γ -dimers [38, 39] . Cross-link formation occurs between Lys 406 on one γ chain and either Gln 399 or Gln 398 on the neighbouring γ chain; however, FXIIIa shows increased specificity for Gln 398 over Gln 399 [40] . There has been much debate regarding the orientation of γ chain cross-links [41, 42] , with several studies suggesting that cross-linked γ chains are longitudinal with isopeptide bonds forming end-to-end between fibrin molecules [43, 44] , whereas others suggest that isopeptide bonds are aligned between fibrin protofibrils in the transverse orientation [45] . Definitive experiments to clarify the orientation are yet to be reported.
The fibrin α chain is cross-linked by FXIIIa to form α-polymers, albeit at a much slower rate compared with γ -γ cross-links [39] . Reactive glutamine residues of the α chain have been located at positions Gln 221 , Gln 237 , Gln 328 and Gln 366 using primary amines [46, 47] . A number of lysine donor sites in the α chain have been identified by their ability to incorporate an N-terminal peptide of α 2 [49] . The multiple lysine donor sites identified in the α chain provide the opportunity for the formation of a complex fibrin polymer while retaining the possibility of cross-linking numerous other plasma proteins to fibrin [47, 48] .
Studies measuring the elastic modulus of fibrin clots suggest that α chain cross-linking increases clot stability and rigidity [50, 51] by promoting protofibril aggregation and the formation of thicker fibres [52] . Clot rigidity is also dependent on the formation of γ chain cross-links. Site-directed mutagenesis of Lys 406 , Gln 399 and Gln 398 within the γ chain has demonstrated that γ -dimers produce maximal clot stiffness, whereas γ -α heteropolymers produce minimal increases in the strength of the fibrin fibres [38] . Fibrin is degraded by plasmin within the coiled-coil located between regions D and E. Resistance of the fibrin clot to plasmin-mediated fibrinolysis was found to be independent of γ -dimer formation [38, 53] , whereas the formation of γ -multimers or highly complex α polymers conferred increased resistance to fibrinolysis [53] .
Cross-linking of FV (Factor V)
FV is a single-chain glycoprotein found in plasma and platelet α-granules. During activation of the coagulation cascade, FV is proteolytically activated by thrombin, resulting in the release of two activation peptides (M r = 150 000 and 71 000) and the formation of FVa (activated FV). FVa binds to FXa (activated Factor X) and is a co-factor for the FXa-mediated cleavage of pro-thrombin, leading to thrombin generation and fibrin formation. FVa is inactivated by cleavage by the natural anticoagulant activated protein C, leading to down-regulation of thrombin generation [54] .
Activated and zymogen FV form high-molecular-mass polymers in the presence of FXIIIa, with cross-linking occurring between the large activation peptide and FVa [22] , suggesting that FV contributes both glutamine and lysine residues in the cross-linking reaction [55] . Putrescine and dansylcadaverine can be incorporated into the large activation peptide of FV by FXIIIa, as determined by SDS/PAGE and fluorography [22] , suggesting the activation peptide contains glutamine residues for the transamidation reaction; however, the specific reactive glutamine and lysine residues of FV have yet to be identified. Cross-linking between FV and other plasma proteins has not been identified and the physiological role of FV crosslinking is unknown; however, cross-linking of either putrescine or dansylcadaverine did not prevent thrombin cleavage of FV, Figure 3 Role of cross-lining in thrombus consolidation and extracellular matrix attachment Following tissue damage, the coagulation cascade is activated to generate thrombin. Thrombin cleaves fibrinogen to form fibrin and activates platelets and plasma FXIII-A. Activated platelets undergo conformational changes due to the cross-linking of cytoskeleton proteins by cFXIII-A and some form COAT platelets, thus aiding pro-thrombinase activity. Plasma FXIII-A cross-links fibrin to produce the structural framework of a thrombus, whereas cross-linking of the fibrinolysis inhibitors during fibrin formation is essential in protecting the forming clot from plasmin-mediated lysis. Cross-linking of matrix proteins fibronectin, collagen and vWF may be important in cell-matrix interactions and cross-linking of PAI-2 and plasminogen to matrix components suggests a role in localized regulation of plasmin generation and matrix metalloproteinase activation.
suggesting the site for thrombin cleavage is accessible following cross-linking [22] .
Cross-linking of thrombospondin-1
Thrombospondin-1 is a glycoprotein released by α-granules of activated platelets and plays a role in platelet aggregation [56] . Thrombospondin-1 covalently incorporates putrescine in the presence of FXIIIa and forms intermolecular crosslinks to itself by assembling as homopolymers, suggesting that thrombospondin-1 can provide both glutamine and lysine residues in the cross-linking reaction [24, 25] , although the specific residues are currently unknown. Thrombospondin-1 partially digested by thrombin incorporated a larger quantity of putrescine compared with the native protein, suggesting that thrombin digestion exposes additional glutamine sites for cross-linking [24] . Radioactively labelled thrombospondin-1 is incorporated into purified and plasma clots, with greater incorporation occurring in the presence of FXIIIa [57] , due to the formation of cross-links between thrombospondin-1 and the fibrin α chain [24, 25] . Cross-linking of thrombospondin-1 into fibrin clots was found to increase the density of the fibrin clot in a concentrationdependent manner [57] , although the effects on fibrin function
have not yet been investigated. In summary, FXIIIa plays a major role in coagulation through the cross-linking of fibrin to produce the structural framework of a thrombus, which is able to withstand mechanical breakdown. The role of FV and thrombospondin-1 cross-linking in thrombus formation remains unclear; however, evidence suggests the function of FV is unaffected by cross-linking, whereas thrombospondin-1 cross-linking influences clot structure and therefore potentially fibrin function.
SUBSTRATES OF FXIII INFLUENCING THE FIBRINOLYTIC SYSTEM
Fibrinolysis is mediated by the serine protease plasmin. Plasmin is produced from the inactive zymogen plasminogen by the PAs (plasminogen activators), u-PA (urokinase-type PA) and t-PA (tissue-type PA). Upon activation, plasmin breaks down fibrin into fibrin degradation products. Regulation of fibrinolysis occurs via several mechanisms, including modulation of plasminogen binding, plasminogen activation and plasmin inhibition. Many of these effects are influenced by FXIIIa-dependent crosslinking reactions, as outlined below and in Figure 3 .
Cross-linking of α 2 -antiplasmin
The serine protease inhibitor α 2 -antiplasmin is a glycoprotein that forms a covalent bond with the active-site serine residue of plasmin, inhibiting plasmin activity and thus plasmin-induced breakdown of fibrin. In plasma there are two N-terminal forms of circulating α 2 -antiplasmin: Met-α 2 -antiplasmin (464 residues) and Asn-α 2 -antiplasmin (452 residues). Met-α 2 -antiplasmin is proteolytically cleaved by APCE (antiplasmin-cleaving enzyme) between Pro 12 and Asn 13 , resulting in Asn-α 2 -antiplasmin. α 2 -Antiplasmin is cross-linked to the fibrin α chain and this reaction occurs 13 times faster for Asn-α 2 -antiplasmin than Met-α 2 -antiplasmin and, as a direct consequence, inhibition of fibrinolysis is more effective upon cross-linking of Asn-α 2 -antiplasmin [58] . Gln 2 within Asn-α 2 -antiplasmin is specifically cross-linked to Lys 303 of the fibrin α chain [31] . Gln 2 was found to be the primary residue susceptible to FXIIIa cross-linking as it readily incorporated [ 14 C]histamine [59] , and a synthetic peptide comprising residues 1-12 of Asn-α 2 -antiplasmin was found to compete with wild-type α 2 -antiplasmin for FXIIIa cross-linking both in a purified [60] and plasma-based [61] system. Mutant Asn-α 2 -antiplasmin, formed by replacing Gln 2 with alanine, incorporated 5-(biotinamido)pentylamine into three alternative sites, including Gln 21 , Gln 419 and Gln 447 , in the presence of FXIIIa, suggesting that FXIIIa has the potential to cross-link a number of sites; however, incorporation at these sites was markedly less efficient compared with Gln 2 [29, 30] . Clots produced from plasma deficient in α 2 -antiplasmin lyse readily, even after suspension into plasma containing physiological concentrations of α 2 -antiplasmin, whereas clots formed using α 2 -antiplasmin-deficient plasma supplemented with α 2 -antiplasmin prior to clotting prevented fibrinolysis in a concentration-dependent manner [62] . Thrombi deficient in either FXIII-A or α 2 -antiplasmin lyse at significantly faster rates compared with thrombi containing both FXIII-A and α 2 -antiplasmin [63] , and incorporation of the synthetic Asn-α 2 -antiplasmin residues 1-12 peptide competed with native α 2 -antiplasmin for cross-linking and accelerated fibrinolysis [61] . These findings highlight the importance of cross-linking of α 2 -antiplasmin to fibrin during clot formation to provide protection from plasmin-mediated lysis.
Cross-linking of thrombin activatable fibrinolysis inhibitor
During fibrinolysis, plasmin cleaves fibrin exposing C-terminal lysine and arginine residues which act as cofactors for plasminogen binding and tPA-mediated plasmin generation. The pro-carboxypeptidase TAFI (thrombin activatable fibrinolysis inhibitor) undergoes proteolysis by the thrombin-thrombomodulin complex to form the carboxypeptidase TAFIa (activated TAFI), which inhibits plasminogen activation and therefore fibrinolysis [64] . TAFIa removes the C-terminal lysine and arginine residues preventing plasminogen binding and plasmin generation. Physiological concentrations (70-250 nM) of TAFIa also inhibit plasmin directly to further inhibit fibrinolysis [64] .
TAFI incorporates both dansylcadaverine and dansyl-PGGQQIV in the presence of FXIIIa and TG2 (tissue transglutaminase 2) forming homopolymers, indicating it contains amine acceptor and donor sites. The reactive glutamine sites have been identified as Gln 2 , Gln 5 and Gln 292 [26] ; however, currently the reactive lysine sites are unknown. TAFI is also cross-linked to fibrin by FXIIIa and TG2 as determined by SDS/PAGE [26] , and Gln 2 and Gln 5 within the activation peptide of TAFI are capable of cross-linking to Lys 212 , Lys 77 and Lys 79 of the fibrin α chain [65] . In plasma and whole-blood thrombi, neutralization of TAFIa by a carboxypeptidase inhibitor conferred an increase in lysis rates [66] , suggesting TAFIa remains functional after crosslinking. FXIIIa-mediated cross-linking of TAFI may therefore serve to localize TAFI to sites of thrombus formation.
Cross-linking of vitronectin
Vitronectin is a plasma glycoprotein present in megakaryocytes and platelet α-granules. Vitronectin is involved in the regulation of coagulation, fibrinolysis, complement and cell adhesion, and is a carrier protein for PAI (PA inhibitor)-1 [67] . Putrescine is readily incorporated into vitronectin in the presence of FXIIIa, as determined by MS analysis, and Edman sequencing of the tryptic peptides indicated the predominant incorporation of putrescine at Gln 93 , with minor incorporation at Gln 73 , Gln 84 and Gln 86 [19] . In the presence of FXIIIa, vitronectin forms homodimers, suggesting that vitronectin contains reactive glutamine and lysine residues [20] ; however, the lysine residues have not been identified. Although vitronectin is incorporated into fibrin clots, this was found to be independent of FXIIIa, suggesting that vitronectin binds rather than is cross-linked to fibrin [67] . Fibrinbound vitronectin is important for PAI-1 binding to fibrin and PAI-1-mediated inhibition of t-PA, suggesting that vitronectin plays an essential role in preventing fibrinolysis [68] . Whether vitronectin is incorporated into other proteins is currently unclear.
Cross-linking of α 2 -macroglobulin α 2 -Macroglobulin is a plasma glycoprotein which inhibits several proteolytic enzymes, such as thrombin and plasmin. α 2 -Macroglobulin binds and forms a complex with plasmin and, although the rate of complex formation is slower than that of α 2 -antiplasmin and plasmin, complex formation begins before α 2 -antiplasmin saturation, supporting a role of α 2 -macroglobulin as a secondary inhibitor of fibrinolysis with physiological relevance [69] . α 2 -Macroglobulin is a substrate for FXIIIa as it readily incorporates dansylcadaverine [21, 28] and putrescine [21] into a major site at Gln 670 and a minor site at Gln 669 [21] . Although α 2 -macroglobulin contains reactive glutamine sites, the substrate(s) to which α 2 -macroglobulin is cross-linked has not been identified to date. Unlike α 2 -antiplasmin, α 2 -macroglobulin is not crosslinked to fibrin [28] , suggesting that α 2 -macroglobulin may be important for the protection of other clot or matrix proteins from proteolytic cleavage.
In summary, FXIIIa-dependent cross-linking of the fibrinolysis inhibitors during fibrin formation is essential in protecting the forming clot from plasmin-mediated lysis. In particular, cross-linking of α 2 -antiplasmin to fibrin appears to be the primary mechanism for FXIIIa-dependent prolongation of fibrinolysis [63] . Cross-linking of TAFI, vitronectin and α 2 -macroglobulin may play a secondary more localized role in the modulation of fibrinolysis and/or proteolysis of extracellular matrix proteins.
SUBSTRATES OF FXIII INFLUENCING CELLULAR FUNCTION AND EXTRACELLULAR MATRIX FORMATION AND STABILITY
A number of cell types contain cFXIII-A, which appears to be located primarily in the cytosol; however, in macrophages the association of cFXIII-A with other compartments, including the nucleus and plasma membrane, has also been described [70] . A previous study found that cFXIII-A is enriched in plasmamembrane-associated structures resembling cell adhesions that also contain certain Golgi proteins [9] , suggesting a possible pathway for externalization of cFXIII-A, which may contribute to the plasma pool. As outlined below, cFXIII-A and plasma FXIII-A contribute to both intracellular and extracellular processes to modulate cell/protein interactions (Figure 3 ).
Cross-linking of the platelet cytoskeleton
The platelet cytoskeleton is made up of actin filaments which provide support to the plasma membrane allowing it to change from a discoidal shape in a resting platelet to a sphere with filopodia in an activated platelet ready for clot retraction. Some of the first cytoskeletal proteins to be identified as FXIIIa substrates were myosin and actin [71, 72] . Fluorescence analysis of dansylcadaverine incorporation into myosin by SDS/PAGE suggested that most of the incorporation occurred in the myosin heavy chain; however, a small amount of incorporation was also observed within the myosin light chain. The myosin heavy chain has been shown to form highly cross-linked polymers in the presence of FXIIIa, suggesting the presence of both FXIIIareactive glutamine and lysine residues [71] . Dansylcadaverine cross-linking to platelet actin occurs at a slow rate, with incubation times of 8 h and high FXIIIa/actin ratios required [72] . Actin subunits also form intermolecular cross-links in the presence of FXIIIa, suggesting this protein also contains FXIIIa-reactive glutamine and lysine residues [72] . A more recent study failed to demonstrate cross-linking of platelet actin in activated platelets; however, platelet activation was essential for binding of cFXIII-A to actin, allowing it to be translocated to the platelet periphery upon actin polymerization [73] . The translocation of cFXIII-A to the platelet periphery may be essential for the cross-linking of cytoskeleton proteins such as vinculin, which is also redistributed to the platelet periphery during platelet activation [74] . Both vinculin and filamin are cross-linked in activated platelets, as demonstrated by the formation of high-molecular-mass complexes; however, platelet aggregation was required for vinculin cross-linking [73] . In platelets deficient in cFXIII-A, binding of fibrinogen is reduced upon thrombin receptor agonist peptide stimulation and platelet spreading is delayed [75] . These findings suggest a role for cFXIII-A in stabilizing and strengthening the platelet cytoskeleton prior to clot retraction. A role for cFXIII-A in clot retraction is supported by studies in FXIII-A-knockout mice in which clot retraction does not occur [76] . Clot retraction following supplementation with plasma FXIII-A was only partially restored, suggesting both extracellular and intracellular FXIII play a role in clot retraction in mice.
Cross-linking in COAT (collagen-and thrombinactivated) platelet formation
COAT platelets are a subset of thrombin and type I and V collagen-activated platelets characterized by the presence of high surface concentrations of α-granule proteins, including FV, fibrinogen, vWF (von Willebrand factor), fibronectin, α 2 -antiplasmin and thrombospondin. The presence of prothrombotic proteins on the surface of COAT platelets make them highly likely to contribute to thrombosis compared with non-COAT platelets. As highlighted above, these proteins are also known FXIIIa substrates, suggesting that FXIIIa-dependent cross-linking may be important in formation of COAT platelets. To confirm this, Dale et al. [77] monitored COAT platelet formation following incubations with dansycadaverine, S4732 (an FXIIIa active-site inhibitor) and antibodies inhibiting FXIII-A activation and activity. By preventing FXIIIa activity the appearance of protein complexes on COAT platelets was significantly reduced, even though protein was still released from α-granules. That study showed further that cross-link formation occurred between released α-granule proteins and serotonin [77] . Szasz and Dale [78] found that proteins cross-linked to serotonin bound to a currently unknown serotonin-binding site on fibrinogen and thrombospondin and proposed a model for COAT platelet formation whereby fibrinogen and FV initially bind to their respective receptors on platelets [GP (glycoprotein) IIb/IIIa and phosphatidylserine], followed by binding of thrombospondin and other proteins cross-linked to serotonin to fibrinogen and thrombospondin via the serotonin-binding sites to form a complex network of proteins [78] . As COAT platelet formation does not occur on all platelets, it suggests that α-granule secretion, FXIII-A activity, phosphatidyl exposure and GPIIb/IIIa activation all need to coincide. The importance COAT platelets and, in particular, serotonin cross-linking in thrombus formation is highlighted in patients undergoing treatment with fluoxetine (which decreases platelet serotonin levels) where a tendency for mild bleeding is observed [79] .
Cross-linking of fibronectin
Fibronectin is a glycoprotein which plays important roles in cell adhesion, migration and tissue repair due to its ability to bind molecules such as cell-surface integrins, fibrin, collagen and heparin [80, 81] . Fibronectin exists in two forms. Plasma fibronectin is a disulfide-bonded dimer produced by hepatocytes, which plays a major role in extracellular matrix formation. Cellular fibronectin is synthesized locally in tissues by a variety of cells, including fibroblasts, myoblasts, macrophages, epithelial cells, smooth muscle cells, hepatocytes, chondrocytes, osteoblasts, Schwann cells and astroglial cells, as dimers and multimers and is more important in mediating cell-matrix interactions rather than matrix formation [82] .
Fibronectin is cross-linked to the fibrin α chain by FXIIIa [83] , initially forming heterodimers, which upon further cross-linking form high-molecular-mass polymers as observed by SDS/PAGE [84] . Early studies of bovine fibronectin demonstrated crosslinking of putrescine to Gln 3 [23] . Corbett et al. [32] subsequently demonstrated that Gln 3 , Gln 4 and Gln 16 were potential crosslinking sites in human fibronectin, as recombinant fibronectin containing mutations at Gln 3 and Gln 4 resulted in a 65 % reduction in cross-linking compared with wild-type fibronectin, and additional mutation at Gln 16 resulted in a complete loss of crosslinking [32] . To date, the lysine residues which participate in fibrin to fibronectin cross-linking have not been determined.
Several studies have investigated the role of fibronectin cross-linking on clot formation. Cross-linking of fibronectin to fibrin produces significantly more dense clots with smaller pores; however, clot rigidity was unaffected by fibronectin at physiological concentrations [84] [85] [86] [87] . Perfusion of platelets over a matrix containing either fibrin or fibronectin alone or crosslinked fibronectin-fibrin in a parallel plate flow chamber indicated increased platelet adhesion and aggregation to cross-linked fibronectin-fibrin compared with fibrin or fibronectin alone [88] .
The extent of platelet thrombus formation was also shown to be dependent on the concentration of fibronectin cross-linked to fibrin [88] . Cross-linking of fibronectin to fibrin is also required for fibroblast adhesion and spreading on fibronectin, suggesting that covalent interactions may induce structural changes within the protein which provide access to the adhesive domain [32] . Crosslinking by FXIIIa is also required for megakaryocyte spreading and fibronectin matrix assembly on spread megakaryocytes incubated on type I collagen [89] . These findings suggest diverse roles for FXIIIa-dependent cross-linking of fibronectin in thrombosis and wound healing, including extracellular matrix assembly, platelet thrombus formation and cell-matrix interactions.
Cross-linking of collagen
Collagen forms a major component of the extracellular matrix and exposure of collagen to flowing blood initiates thrombus formation. Type I, II, III and V collagens are cross-linked by FXIIIa to fibronectin [90, 91] . During the cross-link reaction collagen provides the lysine residues, whereas fibronectin provides the glutamine residues [92] . Although the reactive lysine residue(s) of collagen is currently unknown, type I collagen competitively inhibits the cross-linking of fibronectin to fibrin, suggesting that Gln 3 , Gln 4 or Gln 16 of fibronectin are probable sites for crosslinking to collagen [90] . Cross-linking of fibronectin to collagen may play an important physiological role in extracellular matrix formation and wound healing.
Cross-linking of vWF
vWF is a plasma glycoprotein composed of 250 kDa subunits held together by disulfide links to form large multimers, which are important for vWF-platelet interactions. vWF is present in platelet α-granules and endothelial cell Weibel-Palade bodies, and plays an essential role in the initial adhesion of platelets to subendothelial collagen at sites of vascular injury and as a carrier of FVIII (Factor VIII), providing protection from proteolytic degradation in plasma [93] . Multimeric vWF molecules are not cross-linked to each other by FXIIIa, but can incorporate putrescine, suggesting that only glutamine residues are available for cross-linking [94] . Studies of bovine vWF have shown that Gln 313 , Gln 509 , Gln 560 and Gln 634 are susceptible to FXIIIa cross-linking as dansylcadaverine is readily incorporated at these residues [95] ; however, only Gln 313 and Gln 560 are conserved in human vWF, suggesting these may be the residues involved in cross-linking vWF.
In a purified system, multimeric vWF was found to covalently cross-link to the fibrin α chain as both vWF-α chain heterodimers and high-molecular-mass polymers were observed. vWF was also found to incorporate into fibrin in a plasma-based system; however, clotting times of 3 h were required [94] . In the presence of FXIIIa, vWF is also covalently cross-linked to components of the basement membrane, such as type I and III collagen [96] and laminin [97] . Subendothelial vWF plays an essential role in primary haemostasis by binding to platelet GPIb-IX-V receptors to promote platelet adhesion and thrombus formation at sites of vascular damage; however, the specific role of vWF cross-linking to extracellular matrix components remains unclear.
Cross-linking of plasminogen
Plasminogen is produced by the liver as an inactive precursor, which is converted into the serine protease plasmin upon cleavage by u-PA or t-PA. Plasmin is responsible for fibrinolysis and also the activation of matrix metalloproteinases, which play important roles in tissue repair [98] . Plasminogen incorporates dansylcadaverine and dansyl-PGGQQIV in the presence of FXIIIa, indicating the presence of both reactive glutamine and lysine residues [99] . The incorporation sites were identified as Lys 298 and Gln 322 by Edman sequencing analysis [100] . Plasminogen molecules become cross-linked to each other within 5 min of incubation with FXIIIa, and plasminogen is also cross-linked to fibronectin by FXIIIa and TG2, forming heteropolymers [99] . Plasminogen cross-linking occurs extensively on endothelial cell surfaces and remains activatable by t-PA to form plasmin [99] . This suggests a localized role of plasminogen at the cell surface and extracellular matrix in generating plasmin to limit thrombus formation and in the activation of matrix metalloproteinases involved in matrix remodelling and angiogenesis [101] .
Cross-linking of PAI-2
PAI-1 and PAI-2 form complexes with free PA, preventing plasmin generation and therefore fibrinolysis and proteolysis [102] . PAI-2 is predominantly an intracellular protein expressed in monocytes, endothelial cells, fibroblasts and smooth muscle cells and, as a result, is localized to the extracellular matrix. Although secreted as a 60 kDa glycoprotein, the plasma levels are extremely low [103] , suggesting PAI-2 influences tissue repair by modulating proteolysis at sites of vascular injury. PAI-2 has been shown to be cross-linked to fibrin and contains three glutamine residues susceptible to cross-linking: Gln 83 , Gln 84 and Gln 86 , which are located away from the PAI-2 active site in a 33-amino-acid extended loop region between helices C and D [104] . Recombinant peptides of PAI-2 residues 80-90, mutated at either Gln 83 or Gln 86 demonstrated reduced competition with wild-type PAI-2 for FXIIIa cross-linking [102] . MS analysis of a tryptic peptide containing the three glutamine residues showed that only one putrescine unit is attached to PAI-2 at any one time, suggesting that these sites are not cross-linked simultaneously [104] ; however, the preferred site of incorporation has yet to be defined. PAI-2 is cross-linked to the fibrin α chain [105, 106] located in the flexible C-terminal domain [106] . Fibrin α chain cross-linking was unaffected by the presence of PAI-2 [105] , and PAI-2 cross-linked to fibrin remained functional as both u-PA [102] and t-PA [106] were inhibited in a dose-dependent manner thus preventing fibrinolysis. Although PAI-2 is predominantly an intracellular protein, secreted PAI-2 cross-linked to fibrin may provide localized inhibition of fibrinolysis at the site of vascular damage [102] . Whether PAI-2 is cross-linked to other extracellular matrix proteins is currently unknown.
Cross-linking of AT 1 R (angiotensin type 1 receptor)
AT 1 R is a G-protein-coupled receptor activated by binding of its ligand AngII (angiotensin II), which is formed during activation of the RAS (renin-angiotensin system) [107] . Activation of monocyte AT 1 R results in increased cell activation and adhesion to the endothelium, a process thought to contribute to the increased risk of atherosclerosis seen in hypertensive individuals [107] . Intriguingly AT 1 R signalling is increased in the monocytes of these individuals by the formation of substantial numbers of covalently stabilized AT 1 R homodimers [108] (Figure 4 ). Upon ligand-induced receptor dimerization, monocyte cFXIII-A was shown to cross-link Gln 315 to a currently unknown lysine residue in the cytoplasmic tail domains of the receptor [108] . This cross-linking required both AngII (to promote receptor activation and dimerization) and increased cytosolic Ca 2 + (to promote cFXIII-A activation) and was absent from the monocytes of FXIII-A-deficient patients.
Although monocytes from hypertensive individuals have a greater proportion of AT 1 R molecules present in cross-linked dimers compared with those from healthy controls, lowering AngII levels by treatment with an ACEI [ACE (angiotensin-converting enzyme) inhibitor] significantly reduced receptor cross-linking. Furthermore, inhibition of ACE or of cFXIII-A reduced the development of atherosclerosis in ApoE (apolipoprotein E)-deficient mice, linking in vivo FXIII-A activity to this process [108] .
Cross-linking in cartilage and bone
The potential for FXIII-A to modulate extracellular matrix formation and function is supported by studies of bone and cartilage formation (Figure 4) . FXIII-A and TG2 are the principle transglutaminases expressed in cartilage and bone, being synthesized and secreted into the extracellular matrix by chondrocytes and osteoblasts in respective tissues [109] [110] [111] . Increased expression of both enzymes has been linked to the maturation of both chondrocytes and osteoblasts [112, 113] . In chondrocytes, extracellular FXIII-A has been reported as a ligand of α1β1 integrin, promoting externalization of TG2 [114] . FXIII-A-mediated cross-linking activity has been demonstrated within chondrocytes and in the cartilage and bone matrix, with potential extracellular substrates including, fibronectin and osteopontin [110, 112, [115] [116] [117] . Elevation of FXIII-A expression has also been linked to the differentiation of pre-osteoblasts to osteoblasts [118] promoted by type 1 collagen [111] . cFXIII-A activity has also been shown to enhance the secretion of type I collagen and fibronectin from osteoblasts by stabilization of the microtubule system via glu-tubulin cross-linking, suggesting a role in matrix formation [111, 119] . Several studies have also suggested that this crosslinking is required for proper bone matrix deposition and mineralization, as determined by the use of transglutaminase inhibitors [113, 119] . No obvious abnormal skeletal phenotypes have been reported for FXIII-A − / − or TG2 − / − mice, suggesting a compensatory role of the other transglutaminases in skeletal development [120] . For example, TG2
− / − mice have been found to express higher levels of FXIII-A and TGF-β (transforming growth factor-β) [121] . The synergistic effect of FXIII-A and TG2 has also been observed in chondrocyte differentiation [122] , suggesting that cross-link formation is important for bone and cartilage growth and maintenance; however, these actions can occur via FXIII-A and/or TG2.
FXIIIa-mediated fibronectin cross-linking has also been demonstrated to play a role in megakarocyte function in the bone marrow [89] (Figure 4) . Malara et al. [89] found that FXIII-A is the predominant transglutaminase expressed in megakaryocytes and that, in culture, these cells demonstrate constitutive transglutaminase activity both in the cytoplasm and on the plasma membrane where FXIII-A and fibronectin were found to colocalize. They concluded from these observations, and the effect of small-molecule transglutaminase inhibitors, that FXIIIa is required for stabilization of the megakaryocyte-type I collagen interaction through fibronectin fibrillogenesis, a process that inhibits pro-platelet formation [89] and links bone function to haemostasis.
In summary, cFXIII-A can be found in several cell types, including platelets, monocytes/macrophages, chondrocytes and osteoblast/osteocytes. Although there is increasing evidence to suggest cFXIII-A cross-linking plays a role in platelet cytoskeleton remodelling following platelet activation, the downstream signalling of monocyte AT 1 Rs and bone matrix deposition and mineralization, the intracellular functions of FXIII-A remain largely unexplored and require further investigation. FXIIIa-dependent cross-linking of matrix proteins including fibronectin, collagen and vWF may be important in cell-matrix interactions and crosslinking of PAI-2 and plasminogen to matrix components at sites of vascular injury suggests a role in localization and regulation of plasmin generation and matrix metalloproteinase activation to support an important role in wound healing.
THE SPECIFICITY OF FXIII FOR ITS SUBSTRATES
The transglutaminase family contains a group of structurally related enzymes that catalyse the formation of cross-links. To study the role of the transglutaminase active site in defining substrate specificity Hettasch et al. [123] produced a recombinant chimaera of FXIII-A by exchanging exon 7 of FXIII-A, which codes for the active site, with that of TG2 and evaluated the fibrin cross-link pattern. The chimaera produced fibrin α-γ cross-links, a crosslink pattern similar to that of TG2; however, the efficiency was lower than both wild-type enzymes [123] . Although the findings suggests that the primary amino acid residues which make up the active site play a central role in substrate recognition and catalytic activity, this chimaera did not contain the complete catalytic triad of FXIIIa, which could possibly account for the reduced efficiency of the chimaera compared with the wild-type enzyme.
FXIIIa substrates have been studied to determine consensus sequences that confer FXIII specificity. For example, the γ chain of fibrin and β-casein are both known to be good substrates for FXIIIa; however, they do not contain any common sequence which would suggest specificity of FXIIIa for a particular substrate, suggesting substrate recognition residues are also located away from the reactive glutamine residue [40] . Sugimura et al. [124] screened a phage-displayed peptide library for crosslinking of dansylcadaverine and putrescine by FXIIIa to determine common amino acid sequences which aid recognition of reactive glutamine residues. The FXIIIa-preferred substrate sequence was determined to be QxxØxWP, where x is a non-conserved amino acid and Ø is a hydrophobic amino acid [124] . However, this sequence does not correspond to major plasma substrates of FXIIIa such as fibrin, suggesting the importance of substrate protein structure in modulating interactions with FXIIIa.
As no consensus sequence has been identified, studies have focused on the interactions between FXIII-A and its substrates using nuclear magnetic resonance spectroscopy. Marinescu et al. [125] found that residues located C-terminally from the reactive glutamine within α 2 -antiplasmin interact directly with the active site first by the attachment of the glutamine and neighbouring amino acids to the catalytic triad and secondly by the clustering of hydrophobic amino acid side chains at a secondary site. The possibility of a secondary site was also confirmed by Pénzes et al. [126] as the serial cleavage of residues 7-12 of the Asn-α 2 -antiplasmin peptide (residues 1-12) resulted in the gradual loss of catalytic activity. Within this region hydrophobic residues Leu 10 and Lys 12 were found to promote α 2 -antiplasmin binding to FXIII-A [126] . These findings suggest that the glutamine and surrounding hydrophobic residues are important in substrate recognition and binding.
Consequences of FXIII deficiency in vivo
The importance of FXIII-A in thrombosis and wound healing is emphasized in FXIII deficiency, which is characterized by bleeding, abnormal wound healing and spontaneous miscarriage in females, and occurs as a result of defects in the FXIII-A and FXIII-B subunit genes [127, 128] . In FXIII-A-knockout mice, tail-tip bleeding times are doubled and clot stability, assessed by thromboelastography, was impaired compared with wild-type mice [129] . Equally, the rate of clot retraction is significantly reduced [76] . Impaired tissue repair was observed in the left ventricles of FXIII-A-knockout mice after myocardial infarction. Furthermore, molecular imaging of cross-linking within the infarct of wild-type mice confirmed high FXIII-A activity [130] . In male FXIII-A-knockout mice, fibrosis of the myocardium was observed with deposition of the haemorrhage marker haemosiderin at the site of fibrosis [131] . Wound closure after 11 days was reduced 27 % in FXIII-A-knockout mice compared with wild-type mice, with necrotized fissure formation and delayed re-epithelialization [132] . In FXIII-deficient patients, bleeding is delayed to between 12-36 h following injury [127] , with subcutaneous bleeding the common clinical manifestation of severe FXIII deficiency, where FXIII activity levels are below 5 % of normal [128] . Analysis of whole blood and platelet-free plasma thrombi from an FXIII-A-deficient patient (FXIII-A activity 8 % of normal) under flow, revealed that lysis occurred 4.4-and 5.6-fold faster respectively, compared with thrombi from healthy controls, with only the formation of γ -dimers apparent after 30 min in the FXIII-A-deficient patient [133] . This increase in lysis rate in FXIII-A-deficient patients may be accounted for by the lack of α 2 -antiplasmin cross-linking, as plasma depleted in either FXIII-A and/or α 2 -antiplasmin prolong lysis 9-fold [63] . Impaired wound healing also coincided with reduced FXIII levels in three patients following a myocardial infarction with recurrent myocardial rupture within 7 days [134] . Prophylaxis with FXIII has been shown to be effective at correcting the clinical manifestations of FXIII deficiency in both FXIII-knockout mice [76, 129, 132] and FXIII-deficient patients [127, 128, 133] , supporting the importance of plasma FXIII in thrombus formation and wound healing.
FUTURE DIRECTIONS
In the future, proteomic technologies should be used to extensively catalogue the plasma and cellular substrates of FXIII-A [124] if we are to fully appreciate the influence of FXIII-A in thrombosis and wound healing. A recent study analysing perfused solubilized ex vivo plasma clots from FXIII-A-deficient plasma and pooled plasma from healthy individuals identified proteins involved in inflammation as potentially novel FXIIIa substrates, suggesting FXIIIa-dependent cross-linking influences numerous biological processes [135] . Previous strategies used to identify substrates of TG2 in a protein mixture and an epithelial cell line [136, 137] could be adapted to identify novel substrates of FXIII-A in both cells and plasma; however, the dynamic range of proteins in plasma may require targeted depletion of more abundant proteins to reveal substrates of lower concentrations.
Future diagnostic applications for FXIII-A may include the detection of acute thrombosis using molecular probes, such as a near-IR fluorescent contrast agents [138] and gadoliniumchelating magnetic resonance probes [139] , which can be crosslinked to fibrin by FXIIIa and indicate ongoing thrombin generation and thrombus formation. This technology may be important in the future for determining FXIII-deficient individuals and those with acute thrombosis for targeted therapy. Alternatively, FXIII itself may be analysed as a potential marker for acute thrombosis, as a study has been able to monitor the FXIIIa peptide by ELISA in healthy subjects [140] . The role of FXIII-A in thrombosis makes it a highly desirable target for future antithrombotic agents; however, future agents need to be highly specific and targeted to prevent uncontrolled bleeding.
CONCLUSIONS
FXIII is a Ca 2 + -dependent pro-transglutaminase which forms covalent ε-(γ -glutamyl)lysine cross-links between fibrin fibres and numerous other plasma and intracellular proteins. FXIIIamediated cross-linking is vital for normal clot structure and function, promoting stabilization by preventing enzymatic and mechanical breakdown, supporting extracellular matrix attachment and influencing clot retraction. During wound healing, FXIIIadependent cross-linking is vital to extracellular matrix assembly and cell-matrix interactions. In some cases, the role of substrate cross-linking on clot properties and wound healing has not been studied. FXIIIa is a potentially attractive therapeutic target for the development of novel antithrombotic agents; however, detailed understanding of the role of FXIII in wound healing may be required to gain a clearer understanding of potential adverse effects of FXIII-A inhibition. 
